05:44 AM EDT, 03/11/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Sunday a phase 3 study of its investigational roflumilast cream 0.05% in children two years to five years old with mild to moderate atopic dermatitis met the primary endpoint and all secondary endpoints.

The company said data from the study showed that treatment with the product candidate led to "significant improvements in atopic dermatitis," including disease clearance as early as the first week and reduction in itch within 24 hours of application.

The data also supports "the well-established efficacy, safety, and tolerability profile of roflumilast cream in atopic dermatitis," Arcutis said.